Advanced or Metastatic ER+ Breast Cancer
1 clinical trials · Condition
◉ Watch Advanced or Metastatic ER+ Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers (NCT02734615) | Novartis Pharmaceuticals | 2016-06-14 |
Track Advanced or Metastatic ER+ Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.